Could Donor Matching Help Fecal Transplants to Work Better?Though it may be hard to get past the “ick… +2 More
November 23, 2015
Health Sciences Interviewer: Donor matching for fecal transplants, we'll talk about that next on the Scope. Announcer: Examining the latest research and telling you about the latest break throughs. The Science and Research Show is on The Scope. Interviewer: I'm talking with Dr. June Round, assistant professor in pathology at the University of Utah. Dr. Round, I think most people have heard about fecal transplant by now, but how effective are they really? How Effective Are Fecal Transplants?Dr. Round: So I think people have heard a lot about fecal transplants being for clostridium difficile infections. So they work quite well for this kind of transient infectious organisms. However, people have started to try them for other intestinal inflammatory diseases like inflammatory bowel diseases, such as ulcerative colitis or Crohn's disease and they are less effective. And I think if we now understand how these microbial communities are shaped will help us to better understand how we can make fecal transplants more effective in the future. Interviewer: And that's a good segue to your research. You did fecal transplants in mice and got some very different results depending on how they were done. Dr. Round: So we're working with three different strains of mice, so they kind of represent three different people. But you infect them with the same amount of salmonella, which is now a fairly low dose, something that a human might take from contaminated food and some of these animals would dropped dead within two days. Interviewer: Oh, my gosh. Dr. Round: Other animals would live well over a week and actually clear the infection, so the differences between the susceptibility or resistance of these animals is really huge. And of course there was the third animal which had a very intermediate response. They didn't drop dead, but they got very sick, had a lot of diarrhea, but eventually cleared it after a couple of days. Interviewer: This is just sort of their response before the transplant, is that correct? Dr. Round: That is their baseline response right before the transplant, that's right. Interviewer: Okay. And then once you did the transplants, what were the differences you saw there? Dr. Round: So the animal that was highly susceptible, the one that would drop dead after two days after salmonella infection, if you give the fecal transplant from the highly resistant strain, that susceptible strain now became highly resistant. Meaning that instead of dropping dead after two days, it was able to live for well over a week and then clear the infection. So you can essentially make a susceptible animal highly resistant by simply giving it a fecal transplant. Major Histocompatibility Complex Genes (MHC)Interviewer: So what was different about these different fecal transplants? Dr. Round: The difference between the fecal transplants was that they came from animals that had a different suite of immune genes, and these immune genes are called Major Histocompatibility Complex or MHC, so there's lots of these MHC genes. So express multiple MHC genes and the very different throughout the population. Interviewer: So maybe a little bit like we have different blood types, but more complicated than that. Dr. Round: That's a great example. Interviewer: Do your findings suggest that people with a certain MHC profile will always combat certain infections better than others? Dr. Round: The major point of our paper is really that your MHC type dictates the type of microbes that live on your body. So some people I have an MHC type that selects for really good robust organisms that help them fight off salmonella really well, whereas other people might select for organisms that don't allow them to fight off salmonella very well. The same could be true for some . . . that's why some people get inflammatory bowel disease, some people don't, is you're selecting for just different cohorts of microbes. Certain MHC types are associated with certain infections. Now, people always thought that that was because the immune system was presenting a better suite of antigens and mounting a better immune response. That's what has been thought for decades and decades, so our findings suggest that it's beyond that actually, it's that the MHC is selecting for microbial communities and some microbial communities are better at helping us battle infection. Interviewer: I've been learning about certain companies that are making so called poop pills, where they take healthy donors and offer those as fecal transplants for, I think, right now it's mostly for people affected with the sedate. But what you're saying is that if they did an additional screening step it may help those therapies work better. Dr. Round: Yes, I think for things like infections where the infection lasts a week, it's a very short time frame. I think that the best thing to do would be take it from a very resistant person, resistant to that particular infection because they probably have microbes that are able to fight the infection off. In our case we were testing salmonella infection. Now, if you want to think about the broader picture, the implications of our findings, although I will say that we haven't quite tested it, is that perhaps for more chronic diseases like inflammatory bowel disease you might have to MHC match for microbes. Interviewer: The MHC complex and what it does is the same system for like graft versus host when you donate a kidney for example you have to make sure that you have a match. Dr. Round: That is exactly right. Interviewer: And if you mismatch then you reject that graft. Dr. Round: The one thing that's becoming evident is that you can give probiotics to people. You can give them millions and millions of bacteria in a little pill, but it doesn't always stick in the gut. It kind of gets flushed through. And part of that could be because that person doesn't have immune system that selects and allows for that bacteria to live there. The same is true for fecal transplants. A lot of times to give a fecal transplant to someone and it works for a little bit, it stays in the gut of those people for a little bit, but then eventually those organisms get either competed out, flushed out, they're just not selected for. So our findings suggest that perhaps we can make fecal transplants stick a little bit better if maybe we match the MHC donor to a recipient. We keep talking about this idea of personalized medicine and I think as far as personalized medicine is concerned, we're going to have to couple the genetics of the person, which is going to include the genetics, their immune profiles as well. We're going to have to couple the genetics with the person along with the types of microbial communities. I think if in the future we can put those two together that we can have some really powerful therapeutic interventions in the future. Announcer: Interesting, informative, and all in the name of better health. This is The Scope, University of Utah Health Radio. |
|
Conversation Between “Good” Bacteria and Immune System Is Key to Digestive HealthOur bodies are home to thousands of species of… +1 More
January 22, 2015
Digestive Health
Health Sciences Interviewer: A study gives new insights into how good bacteria work with our body to promote digestive health - up next on The Scope. Announcer: Examining the latest research and telling you about the latest breakthroughs. "The Science and Research Show" is on The Scope. Interviewer: A study published in Cell Host and Microbe is causing us to rethink what the immune system can do, and how it interacts with the good bacteria that live on our bodies. I'm talking with three authors on the study: senior author June Round, assistant professor of Pharmacology at the University of Utah, and co-first authors Jason Kubinak, and Charisse Peterson. Dr. Round: I think the most important thing and the most interesting thing about this particular study is that it really highlights that there is a conversation between our immune system and the microbes that live on our body. It's becoming more and more clear that these microbes are very important for our health, and there's a lot of factors that shape what types of microbes can live on our bodies. Interviewer: Dr. Kubinak, how does that change our thinking from how we considered our microbiome before? Dr. Kubinak: Well, I think within the last 10 years there's been a pretty significant shift in the way we view our interaction with the microbial world from initially primarily focused on antagonistic interactions where hosts and their immune systems were focused on eradicating and eliminating pathogens that make us sick. Whereas now, I think there's a renewed interest in the interaction between the hosts and microbes and how it promotes, or facilitates host health. I think our story sort of gets at that by demonstrating that the crosstalk between host and microbe generally is a health-promoting interaction. Interviewer: So your work, in particular, addresses how the body keeps its balance of species of good bacteria intact, and you're particularly looking at one protein called MyD88. What did we know about this protein before your research? Dr. Round: Its original function was assigned to recognize pathogenic organisms and basically act as the frontline detection to tell our immune system, "There is something going on here, there is a microbe here, so we better turn on our immune response and get rid of the pathogens." What we're really showing here is something very different, that detecting the microbe doesn't necessarily get rid of it here. It's actually helping to shape the types of organisms that live in the gut. Interviewer: So how did you come to that conclusion? Dr. Peterson: What did was we created a mouse that specifically knocked out this protein within a specific immune cell called a T cell. Then it gave us a unique opportunity to ask, what happens when this protein is absent in this immune cell and how does that affect the development of the microbiota as a whole in these animals. Interviewer: So when MyD88 was knocked out of the immune system, it basically lead to an imbalance of the communities, the different species of bacteria in the gut. What does that do to the mouse, itself? Dr. Round: What this lead to was that the animals themselves were more susceptible to inflammatory bowel disease, or an experimental model of inflammatory bowel disease. Interviewer: I don't want to get too graphic, but what does that look like in a mouse? Dr. Round: It's just inflammation within the guts of these animals. They lose weight. Dr. Peterson: They get a severe wasting disease, and they get diarrhea. Dr. Round: I think, for me, the most exciting part of the experiments was when we realized that this sensitivity to inflammatory bowel disease wasn't necessarily just caused by this defect that we had created in the host's immune system. One of the things that was driving this was actually this imbalance within the gut. Our ability to rescue that just by giving these mice healthy microbiota and rescue their disease susceptibility was, to me, the most exciting finding. Interviewer: What do you mean? How did you fix the illness? Dr. Peterson: So many people would refer to this as a fecal transplant. In the lab, we call this a microbiota transplant. You basically get rid of all those bad bugs that have developed in that animal because of their genetic deficiency and you replace them a healthy or with a balanced microbiota, so it's really a microbiota transplant. Obviously this is something that is starting to be done in people with various infections within their guts. Interviewer: Well, right. I have to say, when I started talking about your work with other people in the office, that everyone became really excited when I said that I was going to be talking to you about fecal transplants, which sounds kind of strange. But, it's kind of this new exciting therapy that seems to have some pretty striking results in people as well. Dr. Round: I'm glad to hear that people are excited about fecal transplants as, maybe disgusting as they sound. But to me, it makes sense. We have evolved for a very long time with these organisms, they promote our health, they're beneficial to us. So instead of using something that we chemically synthesized that's not natural, we're now using the microbiota as kind of a natural therapy to restore the balance in our bodies. So I think this is really a viable therapy in the future for multiple diseases, not just for inflammatory bowel disease. Interviewer: I think one of the interesting parts of this study is that it really suggests that there is kind of a co-evolution between the microbiome and ourselves. How do you think about that? Dr. Kubinak: To me, it speaks to the nature of natural selection to have driven the evolution of immune system machinery to promote benign symbiosis between us and our microbes. Interviewer: So they're helping us, but we're also finding ways to help them. Dr. Kubinak: Yeah, I think so. I think our immune systems have developed ways to definitely skew the community toward the presence of individuals who at the very least, are not going to cause us harm. Announcer: Interesting. Informative. And all in the name of better health. This is The Scope Health Sciences Radio. |
|